Open menu Close menu Open Search Close search
DRUGS INDEX | MANUFACTURERS INDEX | ANATOMY | GEOGRAPHY | USA STATISTICS | CHINA STATISTICS | RELIGION | JOBS

Niferex-150 Forte Capsules (Ther-Rx)



  • Description
  • Clinical Pharmacology
  • Indications and Usage
  • Contraindications
  • Warnings
  • Warnings (2)
  • Adverse Reactions
  • Overdosage
  • Dosage and Administration
  • How Supplied



    - Drugs index
    - Manufacturers
    - Feedback

  • DESCRIPTION

    Each powder-filled capsule for oral administration contains:

    Iron

       Ferrochel® * (elemental iron) 80 mg

       Polysaccharide iron (elemental iron) 70 mg

    Vitamin C as Ester-C ®

       Ascorbic acid (as calcium ascorbate) 60 mg

       Threonic acid (as calcium threonate) 0.8 mg

    Folic Acid, USP 1 mg

    Vitamin B 12 (cyanocobalamin) 25 mcg


    * Ferrochel® (ferrous bis-glycinate chelate) is a registered trademark of Albion International, Inc., Clearfield, Utah, and is protected under U.S. Patent Nos. 4,599,152 and 4,830,716.
    Ester-C® is a patented pharmaceutical grade material consisting of calcium ascorbate and calcium threonate. Ester-C® is a licensed trademark of Zila Nutraceuticals, Inc.

    Inactive Ingredients:    Magnesium stearate, silicon dioxide, gelatin, titanium dioxide, FD&C Red No. 40, D&C Red No. 28, FD&C Blue No. 1, pharmaceutical glaze.

    CLINICAL PHARMACOLOGY

    Iron is an essential component in the formation of hemoglobin. Adequate amounts of iron are necessary for effective erythropoiesis. Iron also serves as a cofactor of several essential enzymes, including cytochromes that are involved in electron transport.

    Folic acid is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis. Folic acid is converted in the liver and plasma to its metabolically active form, tetrahydrofolic acid, by dihydrofolate reductase.

    Vitamin B 12 is required for the maintenance of normal erythropoiesis, nucleoprotein and myelin synthesis, cell reproduction and normal growth. Intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B 12 from the gastrointestinal tract.

    INDICATIONS AND USAGE

    Niferex®-150 Forte is indicated for the prevention and treatment of iron deficiency anemia and/or nutritional megaloblastic anemias.

    CONTRAINDICATIONS

    Niferex®-150 Forte is contraindicated in patients with a known hypersensitivity to any of the components of this product. Hemochromatosis and hemosiderosis are contraindications to iron therapy.

    WARNINGS

    Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B 12 is deficient.

    WARNING:    Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

     

    PRECAUTIONS

    General

    Do not exceed recommended dose.

    The type of anemia and the underlying cause or causes should be determined before starting therapy with Niferex®-150 Forte. Since the anemia may be a result of a systemic disturbance, such as recurrent blood loss, the underlying cause or causes should be corrected, if possible.

    Folic Acid

    Folic acid in doses above 1.0 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive. Pernicious anemia should be excluded before using this product since folic acid may mask the symptoms of pernicious anemia.

    Pediatric Use

    Safety and effectiveness in pediatric patients have not been established.

    Geriatric Use

    Clinical studies on this product have not been performed in sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

    ADVERSE REACTIONS

    Adverse reactions with iron therapy may include constipation, diarrhea, nausea, vomiting, dark stools and abdominal pain. Adverse reactions with iron therapy are usually transient.

    Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

    OVERDOSAGE

    The clinical course of acute iron overdosage can be variable. Initial symptoms may include abdominal pain, nausea, vomiting, diarrhea, tarry stools, melena, hematemesis, hypotension, tachycardia, metabolic acidosis, hyperglycemia, dehydration, drowsiness, pallor, cyanosis, lassitude, seizures, shock and coma.

    The oral LD 50 of polysaccharide iron complex was estimated to be greater than 5000 mg iron/kg in the rat. Chronic toxicity studies in rats and dogs administered polysaccharide iron complex showed that a daily dosage of 250 mg iron/kg for three months had no adverse effects.

    DOSAGE AND ADMINISTRATION

    Usual adult dose is 1 capsule daily, or as directed by a physician.

    HOW SUPPLIED

    Niferex®-150 Forte Capsules are red and clear capsules filled with brown powder, imprinted in white ink with "THX" on the cap and "0136" on the body in child-resistant, unit-dose packages of 100 capsules (10 × 10 Unit Dose Packs) (NDC 64011-136-11).

    Store at controlled room temperature 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room Temperature.] Avoid excessive heat 40°C (104° F).

    Avoid freezing.

    Mktd. by Ther-Rx Corp., St. Louis, MO 63044

    U.S. Patent Nos. 4,599,152; 4,822,816; 4,830,716; 5,070,085.

    P4206-1 12/04








    - To bookmark this page (add it to your favorites), please click the image to the left.
    - If you wish to link to this page, you can do so by referring to the URL address below this line.

    https://theodora.com/drugs/niferex_150_forte_capsules_ther_rx.html

    This page was last modified 30-JUN-07
    Copyright © 1995-2021 ITA all rights reserved.